Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
The clinical and biochemical determinants of the fibrinogen response to simvastatin or atorvastatin therapy were assessed in 130 patients with severe polygenic or familial hypercholesterolemia treated in a randomized open-trial format design. Hyperfibrinogenemia was associated with atorvastatin, baseline fibrinogen, and initial concentration and change in concentration of apolipoprotein B or low-density lipoprotein cholesterol.
Wierzbicki
A S
AS
Department of Chemical Pathology, King's College London, Guy's, King's & St. Thomas' Medical School,  United Kingdom. Wierzbicki@kcl.ac.uk
Lumb
P J
PJ
Chik
G
G
Crook
M A
MA
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069059:Atorvastatin; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D012307:Risk Factors; D019821:Simvastatin / Q000008:administration & dosage* / Q000009:adverse effects
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D005340:Fibrinogen; D000069059:Atorvastatin; D019821:Simvastatin